Therapy Areas: Respiratory
Twist Bioscience offers Synthetic RNA Controls to Fight Delta Plus Variants of COVID-19
15 September 2021 - - US-based synthetic DNA provider Twist Bioscience Corp. (NASDAQ: TWST) has started shipping its synthetic RNA reference controls for the SARS-CoV-2 AY.1 and AY.2, more commonly known as Delta Plus, the company said.

Positive synthetic controls are robust reference tools used to confirm the accuracy of an assay and in the case of COVID, help classify and characterize virus samples.

The Twist synthetic controls are designed based on specific SARS-CoV-2 variants, cover the full viral genome and are sequence-verified.

For customers interested in alternative variants of SARS-CoV-2, or synthetic RNA or DNA controls for other sequences, Twist can provide custom controls in multiple formats.

Twist also offers a suite of research tools, including next-generation sequencing products for SARS-CoV-2 as well as a broad respiratory panel and the most comprehensive viral panel.

Customers purchasing synthetic controls are subject to Twist's biosecurity screening protocols and applicable laws and regulations.

Twist Bioscience is a synthetic biology and genomics company that has developed a DNA synthesis platform to industrialize the engineering of biology.

The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by "writing" DNA on a silicon chip.


Related Headlines